Literature DB >> 33549708

Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis.

Kimberley Katleba1, Alan P Lombard2, Maria-Malvina Tsamouri3, Han Bit Baek1, Kristine S Nishida4, Stephen J Libertini1, Alexander J Platero4, Ai-Hong Ma5, Chong-Xian Pan6, Paramita M Ghosh3, Maria Mudryj7.   

Abstract

Bladder cancer (BlCa) exhibits a gender disparity where men are three times more likely to develop the malignancy than women suggesting a role for the androgen receptor (AR). Here we report that BlCa cells express low molecular weight (LMW) AR isoforms that are missing the ligand binding domain (LBD). Isoform expression was detected in most BlCa cells, while a few express the full-length AR. Immunofluorescence studies detect AR in the nucleus and cytoplasm, and localization is cell dependent. Cells with nuclear AR expression exhibit reduced viability and increased apoptosis on total AR depletion. A novel AR-LMW variant, AR-v19, that is missing the LBD and contains 15 additional amino acids encoded by intron 3 sequences was detected in most BlCa malignancies. AR-v19 localizes to the nucleus and can transactivate AR-dependent transcription in a dose dependent manner. AR-v19 depletion impairs cell viability and promotes apoptosis in cells that express this variant. Thus, AR splice variant expression is common in BlCa and instrumental in ensuring cell survival. This suggests that targeting AR or AR downstream effectors may be a therapeutic strategy for the treatment of this malignancy. Published by Elsevier B.V.

Entities:  

Keywords:  Androgen receptor; Apoptosis; Bladder cancer; Isoforms; Splice variants

Mesh:

Substances:

Year:  2021        PMID: 33549708      PMCID: PMC7943249          DOI: 10.1016/j.canlet.2021.01.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  39 in total

Review 1.  Androgen receptor splice variants in the era of enzalutamide and abiraterone.

Authors:  Mary Nakazawa; Emmanuel S Antonarakis; Jun Luo
Journal:  Horm Cancer       Date:  2014-07-22       Impact factor: 3.869

2.  Kidney cancer: Androgen receptor--a new target in renal cell carcinoma?

Authors:  Louise Stone
Journal:  Nat Rev Urol       Date:  2014-07-01       Impact factor: 14.432

3.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

4.  Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium.

Authors:  Congxing Lin; Yan Yin; Kristina Stemler; Peter Humphrey; Adam S Kibel; Indira U Mysorekar; Liang Ma
Journal:  Cancer Res       Date:  2013-08-08       Impact factor: 12.701

5.  Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.

Authors:  Dong Gui Hu; Theresa E Hickey; Connie Irvine; Dhilushi Dodampege Wijayakumara; Lu Lu; Wayne D Tilley; Luke A Selth; Peter I Mackenzie
Journal:  Horm Cancer       Date:  2014-02-26       Impact factor: 3.869

Review 6.  On the origins of the androgen receptor low molecular weight species.

Authors:  Maria Mudryj; Clifford G Tepper
Journal:  Horm Cancer       Date:  2013-07-17       Impact factor: 3.869

7.  Effect of testosterone on the development of bladder tumors and calculi in female rats.

Authors:  S Terada; N Suzuki; K Uchide; K Akasofu; E Nishida
Journal:  Gynecol Obstet Invest       Date:  1992       Impact factor: 2.031

8.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.

Authors:  Zhiyong Guo; Xi Yang; Feng Sun; Richeng Jiang; Douglas E Linn; Hege Chen; Hegang Chen; Xiangtian Kong; Jonathan Melamed; Clifford G Tepper; Hsing-Jien Kung; Angela M H Brodie; Joanne Edwards; Yun Qiu
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

9.  Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion.

Authors:  Jinbo Chen; Yin Sun; Zhenyu Ou; Shuyuan Yeh; Chi-Ping Huang; Bosen You; Yu-Chieh Tsai; Tzong-Jen Sheu; Xiongbing Zu; Chawnshang Chang
Journal:  EMBO Rep       Date:  2020-02-13       Impact factor: 8.807

10.  5α-reductase inhibitors impact prognosis of urothelial carcinoma.

Authors:  Chien-Sheng Wang; Ching-Chia Li; Yung-Shun Juan; Wen-Jeng Wu; Hsiang-Ying Lee
Journal:  BMC Cancer       Date:  2020-09-11       Impact factor: 4.430

View more
  3 in total

Review 1.  The Role of Androgens and Androgen Receptor in Human Bladder Cancer.

Authors:  Elizabeth Martínez-Rojo; Laura Cristina Berumen; Guadalupe García-Alcocer; Jesica Escobar-Cabrera
Journal:  Biomolecules       Date:  2021-04-18

Review 2.  Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans.

Authors:  Maria Malvina Tsamouri; Thomas M Steele; Maria Mudryj; Michael S Kent; Paramita M Ghosh
Journal:  Biomedicines       Date:  2021-10-14

Review 3.  Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy.

Authors:  Hiroki Ide; Hiroshi Miyamoto
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.